Bito L Z
Trans Ophthalmol Soc U K (1962). 1986;105 ( Pt 2):162-70.
Since prostaglandins (PGs) were originally discovered in the eye in a search for the mediators of the ocular irritative responses, it is not surprising that the first decade of research on the ocular effects of these autacoids concentrated on their potential role in inflammation and other pathological processes. It is clear that PGs, like most other biologically active compounds, can have pathological effects when introduced into the eye in sufficiently high doses. More recent studies indicate, however, that PGs are also involved in the normal physiological processes of the eye, and that some PGs effectively reduce intraocular pressure and may actually moderate rather than mediate ocular inflammation. We must therefore consider the eicosanoids as a new class of potential ocular therapeutic agents. This paper reviews the evidence that these autacoids are actively transported by some tissues, including the ciliary epithelium, and considers the role of such transport processes in the ocular and systemic pharmacokinetics of endogenous eicosanoids and their therapeutically applied prodrugs.
由于前列腺素（PGs）最初是在眼睛中发现的，当时是为了寻找眼部刺激反应的介质，因此在对这些自分泌物质的眼部效应进行研究的最初十年里，集中研究它们在炎症和其他病理过程中的潜在作用也就不足为奇了。很明显，与大多数其他生物活性化合物一样，当以足够高的剂量引入眼中时，PGs会产生病理作用。然而，最近的研究表明，PGs也参与眼睛的正常生理过程，并且一些PGs能有效降低眼压，实际上可能减轻而非介导眼部炎症。因此，我们必须将类花生酸视为一类新的潜在眼部治疗药物。本文综述了这些自分泌物质被包括睫状体上皮在内的一些组织主动转运的证据，并探讨了这种转运过程在内源性类花生酸及其治疗用前药的眼部和全身药代动力学中的作用。
